Zepbound and Wegovy are medications used for weight management, but they contain different active ingredients and work differently. Compare Zepbound vs Wegovy by mechanism, weight loss study results, side effects, dosing, cost and other important differences.
Zepbound and Wegovy are prescription medications used for chronic weight management in eligible patients, but they contain different active ingredients and target different incretin pathways. Zepbound contains tirzepatide, while Wegovy contains semaglutide.
Tirzepatide
Semaglutide
Zepbound and Wegovy are different prescription products. Their approved uses, dosing and safety information should be considered according to the specific product labeling and guidance from a healthcare professional.
In the Zepbound vs Wegovy comparison, one of the main differences is how the medications act on incretin pathways. Zepbound contains tirzepatide, which activates both GIP and GLP-1 receptors, while Wegovy contains semaglutide, which activates the GLP-1 receptor.
Zepbound contains tirzepatide, which activates both GIP and GLP-1 receptors. These pathways are involved in appetite, glucose regulation and other metabolic processes.
Wegovy contains semaglutide, which stimulates the GLP-1 receptor. This pathway is involved in appetite, glucose regulation and digestion.
Clinical research helps explain why GLP-1-based treatments have become an important area of modern weight-management care. For Zepbound vs Wegovy, major trials have reported substantial average weight reductions with the active ingredients used in both treatments. SURMOUNT-1 studied tirzepatide, the active ingredient in Zepbound, while STEP 1 studied semaglutide 2.4 mg, the active ingredient and dose used in Wegovy. Because these were separate trials, however, their percentages should not be interpreted as a direct head-to-head comparison.
In SURMOUNT-1, tirzepatide was evaluated at several doses. Average body-weight reductions at week 72 were 15.0%, 19.5% and 20.9% with 5 mg, 10 mg and 15 mg, respectively, compared with 3.1% with placebo.
In STEP 1, semaglutide 2.4 mg was evaluated over 68 weeks. Participants receiving semaglutide had an average body-weight reduction of 14.9%, compared with 2.4% with placebo.
SURMOUNT-1 and STEP 1 were separate clinical trials with different treatment durations and study designs. Their percentages should therefore not be interpreted as a direct comparison of Zepbound and Wegovy, and study averages do not predict an individual person's results.
These results help illustrate why GLP-1-based and related incretin therapies have attracted substantial attention in weight-management research. In their respective trials, both treatments were associated with substantial average weight reduction compared with placebo. When evaluating Zepbound vs Wegovy, the study design, dose, treatment duration, approved use, potential side effects and individual clinical circumstances all remain important considerations.
Take our quick educational quiz to explore GLP-1 topics and questions you may want to discuss with a healthcare professional.
When comparing Zepbound vs Wegovy side effects, both medications commonly cause gastrointestinal symptoms. Nausea, diarrhea, vomiting, constipation and abdominal pain are among the adverse reactions reported with both treatments, although their frequency and overall safety profiles are not identical.
Zepbound and Wegovy have important contraindications, warnings and precautions that are not fully summarized here. Their complete prescribing information should be reviewed for product-specific safety information.
Although Zepbound and Wegovy share several gastrointestinal side effects, they are different prescription medications and their adverse-reaction rates should not be compared directly across separate clinical trials. Individual experiences can also vary.
Zepbound vs Wegovy dosing follows different product-specific dose-escalation schedules. Both are prescription medications administered as once-weekly subcutaneous injections, with treatment generally beginning at a lower dose and increasing gradually according to the prescribing information.
Tirzepatide
Semaglutide
Zepbound and Wegovy have different product-specific dosing schedules and should not be considered interchangeable. Prescribing information and guidance from a qualified healthcare professional should be followed.
The cost of Zepbound vs Wegovy cannot be reduced to a single figure. What a patient ultimately pays can depend on insurance coverage, the approved indication, plan requirements, pharmacy benefits and other eligibility factors.
Tirzepatide
Semaglutide
Insurance policies and coverage requirements can change over time. Zepbound and Wegovy should therefore not be compared using list price alone, because actual coverage and out-of-pocket costs can differ substantially.
Zepbound and Wegovy are different prescription medications used for weight management. Zepbound contains tirzepatide and activates both GIP and GLP-1 receptors, while Wegovy contains semaglutide and acts on the GLP-1 receptor. Their clinical evidence, approved uses, dosing schedules and safety information are also product-specific.
Zepbound contains tirzepatide, which targets GIP and GLP-1 receptors. Wegovy contains semaglutide, which targets the GLP-1 receptor.
Zepbound and Wegovy have been evaluated in their own clinical programs, so results from separate trials should be interpreted in the context of each study.
Approved uses, dosing, contraindications, warnings and other safety information differ between the two products and can change as labeling is updated.
This comparison is for educational purposes and does not replace product labeling or guidance from a qualified healthcare professional.
These Zepbound vs Wegovy FAQs answer common questions about the two prescription products, their active ingredients, drug classes and other frequently searched GLP-1 topics.
Zepbound and Wegovy contain different active ingredients. Zepbound contains tirzepatide, while Wegovy contains semaglutide. Tirzepatide acts on both GIP and GLP-1 receptors, whereas semaglutide acts on the GLP-1 receptor.
Zepbound and Mounjaro are separate prescription products, but both contain the same active ingredient, tirzepatide. Their approved uses and product labeling are specific to each brand.
No. Zepbound contains tirzepatide, while Ozempic contains semaglutide. They are different prescription products with different active ingredients and receptor activity.
Zepbound contains tirzepatide, which has GLP-1 receptor activity but also targets the GIP receptor. It is therefore more specifically described as a dual GIP and GLP-1 receptor agonist.
No. Wegovy does not contain tirzepatide. Its active ingredient is semaglutide, a GLP-1 receptor agonist. Tirzepatide is the active ingredient in Zepbound.
Not exactly. Both involve the GLP-1 pathway, but Zepbound's active ingredient acts on GIP and GLP-1 receptors, while Wegovy's active ingredient acts on the GLP-1 receptor. This is a central pharmacological difference between the two products.
There is no single answer that applies to every patient. Zepbound and Wegovy contain different active ingredients and have product-specific clinical evidence, indications, dosing and safety information. Treatment decisions require consideration of individual medical circumstances by a qualified healthcare professional.
This FAQ provides general educational information and does not replace current product labeling or guidance from a qualified healthcare professional.
This Zepbound vs Wegovy article draws on peer-reviewed clinical research used throughout the comparison, including the SURMOUNT-1 tirzepatide trial and the STEP 1 semaglutide trial.
GLP Versus provides general educational information only. The content on this page is not medical advice and should not be used to diagnose, treat or prevent a medical condition, or as a substitute for advice from a qualified healthcare professional. Prescription medications should only be used as directed by an appropriately licensed healthcare professional.